# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001078782-20-000296
Filing Date
2020-04-29
Accepted
2020-04-29 16:31:49
Documents
6
Period of Report
2020-04-29
Effectiveness Date
2020-04-29

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEFINITIVE 14A PROXY STATEMENT | def14a042420_def14a.htm | DEF 14A | 681820
2 | IMAGE | def14a042420def14a1.jpg | GRAPHIC | 291320
3 | IMAGE | def14a042420def14a2.jpg | GRAPHIC | 357330
4 | IMAGE | def14a042420def14a3.jpg | GRAPHIC | 144203
5 | IMAGE | def14a042420def14a4.jpg | GRAPHIC | 235708
6 | IMAGE | def14a042420def14a5.jpg | GRAPHIC | 165090
| Complete submission text file | 0001078782-20-000296.txt |  | 2327599

Mailing Address 13215 BEE CAVE PARKWAY GALLERIA OAKS B, SUITE 125 AUSTIN TX 78738
Business Address 13215 BEE CAVE PARKWAY GALLERIA OAKS B, SUITE 125 AUSTIN TX 78738 1 (646) 650-1351
VOLITIONRX LTD (Filer) CIK: 0000093314 (see all company filings)

EIN.: 911949078 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-36833 | Film No.: 20830826
SIC: 2835 In Vitro & In Vivo Diagnostic Substances